Security Snapshot

BridgeBio Oncology Therapeutics, Inc. - Common Stock (BBOT) Institutional Ownership

CUSIP: 107924102

13F Institutional Holders and Ownership History from Q3 2025 to Q2 2026

Latest Period

Q2 2026

Institutions Reporting

66

Shares (Excl. Options)

59,128,852

Price

$7.62

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / Common Stock
Symbol
BBOT on Nasdaq
All holders as of 30 Jun 2026
Q2 2026
Total 13F shares
59,128,852
Latest holder snapshot 5 signals
Total 13F value
$450,587,521
Portfolio coverage rank
0%
Share change
+1,593,331
Value change
+$8,271,073
Number of holders
66
Issuer context Names, identifiers, and filing context for this profile. 2 identity fields
Shares outstanding
80,101,228
SEC-reported price per share
$8.82
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • BBOT - BridgeBio Oncology Therapeutics, Inc. - Common Stock is tracked under CUSIP 107924102.
  • 66 institutions reported positions in Q2 2026.
  • 8 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 67 to 66 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from $513,833,746 to $450,587,521.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 66 institutions filings for Q2 2026.

Open SEC evidence

Security key

107924102

Latest holder period

Q2 2026

13F holders

66

13D/G owners

8

CIK / CUSIP context first

Open Q2 2026 holders BBOT full holder history BridgeBio Oncology Therapeutics, Inc. SEC filings BridgeBio Oncology Therapeutics, Inc. company facts BridgeBio Oncology Therapeutics, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
8
Security
BBOT
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Helix Holdings II LLC 23% 17,878,594 Bihua Chen 11 Aug 2025
Chen Bihua 22% $139,095,461 17,878,594 Bihua Chen 01 Jul 2026
BridgeBio Pharma LLC 18% 13,878,554 BridgeBio Pharma LLC 11 Aug 2025
Flynn James E 6.2% 4,885,446 Deerfield Management Company, L.P. 11 Aug 2025
BC Global Opportunities IX LP 5.5% $42,740,663 4,365,747 BC Global Opportunities IX LP 04 Sep 2025
CITADEL ADVISORS LLC 3.2% $29,391,684 2,538,142 Kenneth Griffin 30 Sep 2025
Adage Capital Management, L.P. 1.9% $17,226,651 1,487,621 Adage Capital Management, L.P. 30 Sep 2025
PRICE T ROWE ASSOCIATES INC /MD/ 1.1% $10,248,786 885,042 T. Rowe Price Associates, Inc. 30 Sep 2025

As of 30 Jun 2026, 66 institutional investors reported holding 59,128,852 shares of BridgeBio Oncology Therapeutics, Inc. - Common Stock (BBOT). This represents 74% of the company’s total 80,101,228 outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
70%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Cormorant Asset Management, LP 22% 17,878,594 0% 7% $136,234,886
DEERFIELD MANAGEMENT COMPANY, L.P. 6.1% 4,885,446 0% 0.39% $37,227,099
Omega Fund Management, LLC 4.1% 3,289,661 0% 13% $25,067,217
Alphabet Inc. 3.5% 2,823,126 0% 0.02% $21,512,220
EcoR1 Capital, LLC 3.5% 2,823,126 0% 1.1% $21,512,220
WELLINGTON MANAGEMENT GROUP LLP 3.5% 2,789,302 -1% 0% $21,254,481
ENAVATE SCIENCES GP, LLC 3.3% 2,626,946 0% 5.8% $20,017,329
CITADEL ADVISORS LLC 3.3% 2,617,827 +3.5% 0.01% $19,947,841
NOVO HOLDINGS A/S 2.8% 2,250,000 +2.9% 1% $17,145,000
BlackRock, Inc. 2.7% 2,154,040 +3.1% 0% $16,413,785
VANGUARD CAPITAL MANAGEMENT LLC 2.5% 2,005,649 +272% 0% $15,283,045
Laurion Capital Management LP 2.5% 2,002,701 +4.2% 1.1% $15,260,582
ARMISTICE CAPITAL, LLC 2.2% 1,764,000 +33% 0.37% $13,441,680
STATE STREET CORP 1.3% 1,036,569 +358% 0% $7,898,656
Aisling Capital Management LP 1.3% 1,018,018 0% 1.6% $7,757,297
Opaleye Management Inc. 0.87% 700,000 +1214% 0.48% $5,334,000
GEODE CAPITAL MANAGEMENT, LLC 0.78% 622,351 +7.4% 0% $4,744,649
Granahan Investment Management, LLC 0.7% 558,526 +142% 0.15% $4,255,968
SPHERA FUNDS MANAGEMENT LTD. 0.58% 460,985 0.5% $3,512,706
ADAGE CAPITAL PARTNERS GP, L.L.C. 0.5% 400,000 0% 0% $3,048,000
ROYCE & ASSOCIATES LP 0.48% 384,941 -40% 0.02% $2,933,250
Catalio Capital Management, LP 0.4% 318,407 0.46% $2,426,261
PRICE T ROWE ASSOCIATES INC /MD/ 0.37% 300,000 -31% 0% $2,286,000
VANGUARD FIDUCIARY TRUST CO 0.36% 291,522 +15% 0% $2,221,398
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.36% 286,518 -1.5% 0% $2,183,267

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
4
Latest
Q2 2026
Rows shown
1-4 of 4
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q2 59,128,852 $450,587,521 +$8,271,073 $7.62 66
2026 Q1 57,435,188 $513,833,746 -$6,100,446 $8.95 67
2025 Q4 57,897,060 $724,704,890 +$13,675,814 $12.52 52
2025 Q3 56,812,363 $657,547,712 +$657,547,712 $11.58 41
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .